EC Number   |
Protein Variants |
Reference |
|---|
   5.1.3.17 | H584A |
site-directed mutagenesis, the mutant shows 80% reduced activity compared to wild-type |
748202 |
| 5.1.3.17 | more |
construction of enzyme deficient strains ussing P-element transposase exscision mutagenesis, removal of the entire Hsepi coding sequence, generation of viable and fertile homozygous mutants for Hsepid12 and Hsepid13 |
727967 |
| 5.1.3.17 | more |
generation of a soluble form of the enzyme HG-5epi by replacement of the transmembrane domain (N-terminal 33 amino acids) with the immunoglobulin Kappa signal sequence and a FLAG tag |
747914 |
| 5.1.3.17 | more |
generation of Glce null mutant mice, that show a strongly reduced size of the fetal spleen and a spectrum of defects in thymus and lymph node development ranging from dislocation to complete loss of the organ, overview. Transplantation of wild-type lymph nodes allows undisturbed lymphocyte maturation, phenotype, overview |
-, 704951 |
| 5.1.3.17 | more |
generation of Hsepi null mutant mice showing a lethal phenotype with selective organ defects but remarkably little effect on other organ systems, phenotype, overview. Heparan sulfate produced by enzyme-deficient MEF cells is devoid of L-iduronic acid residues, but shows up-regulated N- and 6-O-sulfation compared with wild-type, Hsepi-/- MEF cells proliferate and migrate similarly to wild-type cells. Restricted proliferation and migration of Hsepi mutant cells in response to FGF2 stimulation |
704486 |
| 5.1.3.17 | more |
high cell density fed-batch cultivation of recombinant Escherichia coli strains expressing 2-O-sulfotransferase and C5-epimerase at high level for the production of bioengineered heparin, method, overview. The first enzymatic step in this process uses heparan sulfate biosynthetic enzymes, 2-O-sulfotransferase (2-OST) and C5-epimerase (C5-epi), expressed as MBP-tagged proteins in Escherichia coli, to convert N-sulfo heparosan into an intermediate polysaccharide rich in -GlcNS(1->4)IdoA2S- sequences (where S is sulfo and IdoA is alpha-L-iduronic acid). This critical step in bioengineered heparin preparation relies on the use of recombinant arylsulfotransferase IV (AST-IV) to regenerate 3'-phospho adenosine-5'-phosphosulfate (PAPS) using p-nitrophenylsulfate as a sacrificial sulfur donor, one-pot reaction |
746780 |
| 5.1.3.17 | N585A |
site-directed mutagenesis, the mutant shows 90% reduced activity compared to wild-type |
748202 |
| 5.1.3.17 | R154A |
site-directed mutagenesis, the mutant shows 60% reduced activity compared to wild-type |
748202 |
| 5.1.3.17 | R156A |
site-directed mutagenesis, the mutant shows over 90% reduced activity compared to wild-type |
748202 |
| 5.1.3.17 | R396A |
site-directed mutagenesis, the mutant shows 90% reduced activity compared to wild-type |
748202 |
